Case number 1:19-cv-02309
Taiho Pharmaceutical Co., Ltd. et al v. Eugia Pharma Specialities Ltd. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| May 16, 2024 | 174 | Official Transcript of Pretrial Conference held on 03-21-2024 before Judge Hall. Court Reporter Stacy Ingram,Email: stacy_ingram@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 6/6/2024. Redacted Transcript Deadline set for 6/17/2024. Release of Transcript Restriction set for 8/14/2024. (Ingram, Stacy) (Entered: 05/16/2024) (0) |
| Apr 5, 2024 | 173 | REDACTED VERSION of (202 in 1:19-cv-02368-JLH) Proposed Pretrial Order,, by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20)(Biggs, Brian) (Entered: 04/05/2024) (0) |
| Apr 4, 2024 | 172 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE46,284 E; 10,138,223 B2. (Attachments: # 1 Stipulation of Dismissal)(ceg) (Entered: 04/04/2024) (0) |
| Apr 3, 2024 | 171 | SO ORDERED, re (168 in 1:19-cv-02309-JLH, 19 in 1:23-cv-01193-JLH, 19 in 1:22-cv-01611-JLH, 117 in 1:21-cv-00838-JLH) Stipulation and Order of Dismissal between Plaintiffs and Defendants Eugia Pharma Specialties Ltd., Aurobindo Pharma Ltd., and AurobindoPharma USA, Inc. Signed by Judge Jennifer L. Hall on 4/3/2024. Associated Cases: 1:19-cv-02309-JLH, 1:21-cv-00838-JLH, 1:22-cv-01611-JLH, 1:23-cv-01193-JLH(ceg) (Entered: 04/03/2024) (3) |
| Apr 2, 2024 | 168 | STIPULATION of Dismissal with Prejudice by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Whitesell, Angela) (Entered: 04/02/2024) (3) |
| Apr 2, 2024 | 169 | Letter to Judge Jennifer L. Hall from Brian A. Biggs regarding Settlement by Eugia Defendants. (Biggs, Brian) (Entered: 04/02/2024) (1) |
| Apr 2, 2024 | 170 | ORAL ORDER: Having reviewed the parties' letter (C.A. No. 19-2309, D.I. 169; C.A. No. 19-2342, D.I. 242; C.A. No. 19-2368, D.I. 211) and being advised that the Eugia defendants have settled (see C.A. No. 19-2309, D.I. 168), IT IS HEREBY ORDERED that the parties' trial time is reduced to 9.5 hours per side. Ordered by Judge Jennifer L. Hall on 4/2/2024. Associated Cases: 1:19-cv-02309-JLH, 1:19-cv-02342-JLH, 1:19-cv-02368-JLH(twk) (Entered: 04/02/2024) (0) |
| Apr 1, 2024 | 167 | SO ORDERED, re 166 MOTION for Exemption from the Court's Standing Order on Personal Electronic Devices. Signed by Judge Jennifer L. Hall on 4/1/2024. (twk) (Entered: 04/01/2024) (2) |
| Mar 29, 2024 | 166 | MOTION for Exemption from the Court's Standing Order on Personal Electronic Devices - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Whitesell, Angela) (Entered: 03/29/2024) (6) |
| Mar 25, 2024 | 164 | STIPULATION TO EXTEND TIME to Submit Redacted Verson of the Proposed Final Pretrial Order to April 5, 2024 - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Larson, Erin) (Entered: 03/25/2024) (2) |
| Mar 25, 2024 | 165 | SO ORDERED, re (164 in 1:19-cv-02309-JLH, 238 in 1:19-cv-02342-JLH, 205 in 1:19-cv-02368-JLH) Stipulation and Order to Extend Time to Submit Redacted Verson of the Proposed Final Pretrial Order to April 5, 2024. Signed by Judge Jennifer L. Hall on 3/25/2024. Associated Cases: 1:19-cv-02309-JLH, 1:19-cv-02342-JLH, 1:19-cv-02368-JLH(ceg) (Entered: 03/25/2024) (2) |
| Mar 21, 2024 | 163 | ORAL ORDER: IT IS HEREBY ORDERED that, as discussed at today's pretrial conference, the Proposed Pretrial Order (C.A. 19-2309, D.I. 160; C.A. 19-2342, D.I. 234; C.A. 19-2368, D.I. 202) will be ADOPTED; MSN's Motion to Strike and Daubert Motion to Exclude (C.A. 19-2342, D.I. 203) are DENIED; and Natco's Motion in Limine (C.A. 19-2309, D.I. 160, Ex. 20; C.A. 19-2342, D.I. 234, Ex. 20; C.A. 19-2368, D.I. 202, Ex. 20) is DENIED. IT IS FURTHER ORDERED that the bench trial will begin on April 8, 2024, at 9:30 AM in Courtroom 6D; each side shall have 11 hours for its opening statement, affirmative evidence, and rebuttal evidence (subject to revision should a party settle). IT IS FURTHER ORDERED that, on or before April 5, 2024, at 12:00 PM, the parties shall (1) file with the court a letter listing witness names and technical terms for the court reporter, (2) provide electronic versions of all trial exhibits via email to jlh_civil@ded.uscourts.gov or via a thumb drive delivered to the court. Ordered by Judge Jennifer L. Hall on 3/21/2024. Associated Cases: 1:19-cv-02309-JLH, 1:19-cv-02321-JLH, 1:19-cv-02342-JLH, 1:19-cv-02368-JLH(twk) (Entered: 03/21/2024) (0) |
| Mar 18, 2024 | 162 | Letter to Judge Jennifer L. Hall from Brian A. Biggs regarding response to Defendants March 14, 2024 letter - re (235 in 1:19-cv-02342-JLH, 161 in 1:19-cv-02309-JLH) Letter. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Biggs, Brian) (Entered: 03/18/2024) (0) |
| Mar 14, 2024 | 160 | [SEALED] Proposed Pretrial Order by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Certificate of Service)(Biggs, Brian) (Main Document 160 replaced on 3/15/2024) (ceg). (Attachment 2 replaced on 3/15/2024) (ceg). (Attachment 11 replaced on 3/20/2024) (ceg). (Entered: 03/14/2024) (0) |
| Mar 14, 2024 | 161 | Letter to The Honorable Jennifer L. Hall from Daniel A. Taylor regarding a Claim Construction Dispute with respect to the '666 and '223 Patents raised in the Joint Pretrial Order. (Taylor, Daniel) (Entered: 03/14/2024) (2) |
| Jan 9, 2024 | 158 | MOTION for Pro Hac Vice Appearance of Attorney Catherine Huang and Meera Midha - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Whitesell, Angela) (Entered: 01/09/2024) (6) |
| Jan 9, 2024 | 159 | Pro Hac Vice Fee - Credit Card Payment received for Catherine Huang and Meera Midha. ( re 158 MOTION for Pro Hac Vice Appearance of Attorney Catherine Huang and Meera Midha )( Payment of $ 100, receipt number ADEDC-4310632).(Whitesell, Angela) (Entered: 01/09/2024) (0) |
| Dec 26, 2023 | 157 | ORAL ORDER: Having reviewed the parties' letter to the Court, (C.A. 19-2309, D.I. 156; C.A. 19-2321, D.I. 170; C.A. 19-2342, D.I. 195; C.A. 19-2368, D.I. 195), IT IS HEREBY ORDERED that (1) The 4-day bench trial is rescheduled from March 4, 2024 to April 8, 2024; and (2) The pretrial conference is rescheduled from February 26, 2024 to March 21, 2024 at 3:00 pm in Courtroom 6D. The Court will determine the number of trial days at the pretrial conference. Ordered by Judge Jennifer L. Hall on 12/26/2023. Associated Cases: 1:19-cv-02309-JLH, 1:19-cv-02321-JLH, 1:19-cv-02342-JLH, 1:19-cv-02368-JLH(ceg) (Entered: 12/26/2023) (0) |
| Dec 11, 2023 | 156 | Joint Letter to The Honorable Jennifer L. Hall from Daniel A. Taylor regarding trial dates for asserted claims of the 833, 666, and 223 patents (the "polymorph" patents). (Taylor, Daniel) (Entered: 12/11/2023) (1) |
| Dec 1, 2023 | 155 | ORAL ORDER: IT IS HEREBY ORDERED that a 4-day bench trial on the asserted claims of the '833, '666, and '223 patents will begin on Monday, March 4, 2024 at 9:30 AM before Judge Hall in courtroom 6D. A final pretrial conference shall be held on February 26, 2024 at 3:00 PM. The joint proposed pretrial order will be due in accordance with the Local Rules. Ordered by Judge Jennifer L. Hall on 12/1/2023. Associated Cases: 1:19-cv-02309-JLH, 1:19-cv-02321-JLH, 1:19-cv-02342-JLH, 1:19-cv-02368-JLH(ceg) (Entered: 12/01/2023) (0) |
| Nov 22, 2023 | 154 | ORAL ORDR: A Status Telephone Conference is scheduled for December 1, 2023 at 10:00 AM before Judge Jennifer L. Hall. The parties shall call the Court's conference line at (877) 336-1829, access code: 7090640. Ordered by Judge Jennifer L. Hall on 11/22/2023. Associated Cases: 1:19-cv-02309-JLH, 1:19-cv-02321-JLH, 1:19-cv-02342-JLH, 1:19-cv-02368-JLH(ceg) (Entered: 11/22/2023) (0) |
| Nov 17, 2023 | 153 | CONSENT to Jurisdiction by U.S. Magistrate Judge filed by Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd., Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. Case reassigned to Magistrate Judge Jennifer L. Hall. Signed by Judge Colm F. Connolly on 11/17/2023. (nmf) (Entered: 11/17/2023) (6) |
| Nov 16, 2023 | 151 | Official Transcript of Motion Hearing held on 11/8/23 before Judge Colm Connolly. Court Reporter Deanna Warner, Email: deanna_warner@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 12/7/2023. Redacted Transcript Deadline set for 12/18/2023. Release of Transcript Restriction set for 2/14/2024. (Warner, Deanna) (Entered: 11/16/2023) (30) |
| Nov 16, 2023 | 152 | Joint NOTICE of Consent to Proceed Before a United States Magistrate Judge by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. (Whitesell, Angela) (Entered: 11/16/2023) (6) |
| Sep 25, 2023 | 150 | Joint REPLY BRIEF re 144 MOTION for Entry of Judgment under Rule 54(b) filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd.. (Dorsney, Kenneth) (Entered: 09/25/2023) (17) |
| Sep 15, 2023 | 149 | ANSWERING BRIEF in Opposition re 144 MOTION for Entry of Judgment under Rule 54(b) Plaintiffs' Brief in Opposition to Defendants' Motion for Certification Under Rule 54(b) filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..Reply Brief due date per Local Rules is 9/22/2023. (Attachments: # 1 Verification)(Biggs, Brian) (Entered: 09/15/2023) (0) |
| Sep 13, 2023 | 148 | MOTION for Pro Hac Vice Appearance of Attorney Marcelo Barros - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Larson, Erin) (Entered: 09/13/2023) (5) |
| Sep 1, 2023 | 144 | MOTION for Entry of Judgment under Rule 54(b) - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Text of Proposed Order)(Farnan, Kelly) (Main Document 144 replaced on 9/26/2023) (jfm). (Entered: 09/01/2023) (0) |
| Sep 1, 2023 | 145 | OPENING BRIEF in Support re 144 MOTION for Entry of Judgment under Rule 54(b) filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..Answering Brief/Response due date per Local Rules is 9/15/2023. (Dorsney, Kenneth) (Entered: 09/01/2023) (17) |
| Sep 1, 2023 | 146 | Letter to Chief Judge Colm F. Connolly from Tyler E. Cragg regarding Defendants' Proposed Final Judgment - re (183 in 1:19-cv-02368-CFC-JLH, 144 in 1:19-cv-02309-CFC, 180 in 1:19-cv-02342-CFC-JLH, 154 in 1:19-cv-02321-CFC) MOTION for Entry of Judgment under Rule 54(b) . (Attachments: # 1 Text of Proposed Order)(Cragg, Tyler) (Entered: 09/01/2023) (0) |
| Sep 1, 2023 | 147 | Letter to The Honorable Colm F. Connolly from Brian A. Biggs regarding regarding proposed form of judgment. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Biggs, Brian) (Entered: 09/01/2023) (0) |
| Aug 24, 2023 | 143 | STIPULATION TO EXTEND TIME to Submit Proposed Order regarding Judgment to September 1, 2023 - filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd.. (Dorsney, Kenneth) (Entered: 08/24/2023) (6) |
| Aug 22, 2023 | 141 | STIPULATION TO EXTEND TIME to submit a Proposed Order to August 25, 2023 - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Whitesell, Angela) (Entered: 08/22/2023) (6) |
| Aug 22, 2023 | 142 | SO ORDERED, re (141 in 1:19-cv-02309-CFC, 151 in 1:19-cv-02321-CFC, 177 in 1:19-cv-02342-CFC-JLH, 180 in 1:19-cv-02368-CFC-JLH) STIPULATION TO EXTEND TIME to submit a Proposed Order to August 25, 2023 filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc. NO FURTHER EXTENSIONS SHALL BE GRANTED BEYOND SEPTEMBER 5, 2023. Signed by Judge Colm F. Connolly on 8/22/2023. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC-JLH, 1:19-cv-02368-CFC-JLH(nmf) (Entered: 08/22/2023) (6) |
| Aug 15, 2023 | 139 | OPINION. Signed by Judge Colm F. Connolly on 8/15/2023. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC-JLH, 1:19-cv-02368-CFC-JLH(kmd) (Entered: 08/15/2023) (69) |
| Aug 15, 2023 | 140 | ORDER. The parties shall submit no later thanAugust 22, 2023, a proposed order by which the Court may enter final judgmentconsistent with the Opinion issued this day. Signed by Judge Colm F. Connolly on 8/15/2023. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC-JLH, 1:19-cv-02368-CFC-JLH(kmd) (Entered: 08/15/2023) (3) |
| Aug 7, 2023 | 138 | NOTICE of Withdrawal of Counsel by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. (Balick, Steven) (Entered: 08/07/2023) (3) |
| Jul 14, 2023 | 137 | NOTICE of Withdrawal of Appearance of Christian F. Chessman by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc. (Whitesell, Angela) (Entered: 07/14/2023) (3) |
| May 15, 2023 | 134 | APPENDIX re (164 in 1:19-cv-02342-CFC-JLH, 130 in 1:19-cv-02309-CFC, 140 in 1:19-cv-02321-CFC, 169 in 1:19-cv-02368-CFC-JLH) Proposed Findings of Fact (Volume I of III; Exhibits DTX0008-JTX0151) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit part 1, # 2 Exhibit part 2)(Mayo, Andrew) (Entered: 05/15/2023) (Main Document) (9) |
| May 15, 2023 | 135 | APPENDIX re (144 in 1:19-cv-02321-CFC, 168 in 1:19-cv-02342-CFC-JLH, 134 in 1:19-cv-02309-CFC, 173 in 1:19-cv-02368-CFC-JLH) Appendix, (Volume II of III; Exhibits PTX0467-PTX2003) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit part 1, # 2 Exhibit part 2)(Mayo, Andrew) (Entered: 05/15/2023) (Main Document) (3) |
| May 15, 2023 | 136 | APPENDIX re (134 in 1:19-cv-02309-CFC, 173 in 1:19-cv-02368-CFC-JLH, 144 in 1:19-cv-02321-CFC, 168 in 1:19-cv-02342-CFC-JLH) Appendix, (Volume III of III; Trial Transcripts) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit Trial Transcripts)(Mayo, Andrew) (Entered: 05/15/2023) (Main Document) (3) |
| May 15, 2023 | 135 | APPENDIX re (144 in 1:19-cv-02321-CFC, 168 in 1:19-cv-02342-CFC-JLH, 134 in 1:19-cv-02309-CFC, 173 in 1:19-cv-02368-CFC-JLH) Appendix, (Volume II of III; Exhibits PTX0467-PTX2003) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit part 1, # 2 Exhibit part 2)(Mayo, Andrew) (Entered: 05/15/2023) (Exhibit part 1) (30) |
| May 15, 2023 | 135 | APPENDIX re (144 in 1:19-cv-02321-CFC, 168 in 1:19-cv-02342-CFC-JLH, 134 in 1:19-cv-02309-CFC, 173 in 1:19-cv-02368-CFC-JLH) Appendix, (Volume II of III; Exhibits PTX0467-PTX2003) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit part 1, # 2 Exhibit part 2)(Mayo, Andrew) (Entered: 05/15/2023) (Exhibit part 2) (30) |
| May 15, 2023 | 134 | APPENDIX re (164 in 1:19-cv-02342-CFC-JLH, 130 in 1:19-cv-02309-CFC, 140 in 1:19-cv-02321-CFC, 169 in 1:19-cv-02368-CFC-JLH) Proposed Findings of Fact (Volume I of III; Exhibits DTX0008-JTX0151) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit part 1, # 2 Exhibit part 2)(Mayo, Andrew) (Entered: 05/15/2023) (Exhibit part 1) (30) |
| May 15, 2023 | 134 | APPENDIX re (164 in 1:19-cv-02342-CFC-JLH, 130 in 1:19-cv-02309-CFC, 140 in 1:19-cv-02321-CFC, 169 in 1:19-cv-02368-CFC-JLH) Proposed Findings of Fact (Volume I of III; Exhibits DTX0008-JTX0151) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit part 1, # 2 Exhibit part 2)(Mayo, Andrew) (Entered: 05/15/2023) (Exhibit part 2) (30) |
| May 15, 2023 | 136 | APPENDIX re (134 in 1:19-cv-02309-CFC, 173 in 1:19-cv-02368-CFC-JLH, 144 in 1:19-cv-02321-CFC, 168 in 1:19-cv-02342-CFC-JLH) Appendix, (Volume III of III; Trial Transcripts) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit Trial Transcripts)(Mayo, Andrew) (Entered: 05/15/2023) (Exhibit Trial Transcripts) (30) |
| May 12, 2023 | 132 | Letter to The Honorable Colm F. Connolly from Andrew C. Mayo regarding Taiho's hyperlinked post-trial briefing. (Mayo, Andrew) (Entered: 05/12/2023) (1) |
| May 12, 2023 | 133 | Letter to The Honorable Colm F. Connolly from Tyler E. Cragg regarding USB Drives Containing Defendants' Hyperlinked Post-Trial Briefs - re (132 in 1:19-cv-02321-CFC, 123 in 1:19-cv-02309-CFC, 156 in 1:19-cv-02342-CFC-JLH, 161 in 1:19-cv-02368-CFC-JLH) Order,,. (Cragg, Tyler) (Entered: 05/12/2023) (2) |
| May 11, 2023 | 131 | POST TRIAL BRIEF (Defendants' Reply) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Certificate of Compliance)(Farnan, Kelly) (Entered: 05/11/2023) (Main Document) (30) |
| May 11, 2023 | 131 | POST TRIAL BRIEF (Defendants' Reply) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Certificate of Compliance)(Farnan, Kelly) (Entered: 05/11/2023) (Certificate of Compliance) (1) |
| May 4, 2023 | 129 | POST TRIAL BRIEF (Plaintiffs' Answering Post-Trial Brief) by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc.. (Balick, Steven) (Main Document 129 replaced on 5/11/2023) (nmf, ). (Entered: 05/04/2023) (30) |
| May 4, 2023 | 130 | Proposed Findings of Fact by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Balick, Steven) (Main Document 130 replaced on 5/11/2023) (nmf, ). (Entered: 05/04/2023) (30) |
| May 1, 2023 | 128 | Unopposed MOTION for Extension of Time to File Post-Trial Brief and Findings of Fact - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Biggs, Brian) (Entered: 05/01/2023) (4) |
| Apr 27, 2023 | 126 | NOTICE of Appearance by Brian A. Biggs on behalf of Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. (Biggs, Brian) (Entered: 04/27/2023) (2) |
| Apr 27, 2023 | 127 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Raymond Miller, Shuzo Maruyama, Christian Chessman, and Megan E. Bowers - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Raymond Miller, # 4 Certification of Shuzo Maruyama, # 5 Certification of Christian Chessman, # 6 Certification of Megan E. Bowers)(Biggs, Brian) (Entered: 04/27/2023) (Main Document) (2) |
| Apr 27, 2023 | 127 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Raymond Miller, Shuzo Maruyama, Christian Chessman, and Megan E. Bowers - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Raymond Miller, # 4 Certification of Shuzo Maruyama, # 5 Certification of Christian Chessman, # 6 Certification of Megan E. Bowers)(Biggs, Brian) (Entered: 04/27/2023) (Text of Proposed Order) (1) |
| Apr 27, 2023 | 127 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Raymond Miller, Shuzo Maruyama, Christian Chessman, and Megan E. Bowers - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Raymond Miller, # 4 Certification of Shuzo Maruyama, # 5 Certification of Christian Chessman, # 6 Certification of Megan E. Bowers)(Biggs, Brian) (Entered: 04/27/2023) (Certification of Michael Sitzman) (1) |
| Apr 27, 2023 | 127 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Raymond Miller, Shuzo Maruyama, Christian Chessman, and Megan E. Bowers - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Raymond Miller, # 4 Certification of Shuzo Maruyama, # 5 Certification of Christian Chessman, # 6 Certification of Megan E. Bowers)(Biggs, Brian) (Entered: 04/27/2023) (Certification of Raymond Miller) (1) |
| Apr 27, 2023 | 127 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Raymond Miller, Shuzo Maruyama, Christian Chessman, and Megan E. Bowers - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Raymond Miller, # 4 Certification of Shuzo Maruyama, # 5 Certification of Christian Chessman, # 6 Certification of Megan E. Bowers)(Biggs, Brian) (Entered: 04/27/2023) (Certification of Shuzo Maruyama) (1) |
| Apr 27, 2023 | 127 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Raymond Miller, Shuzo Maruyama, Christian Chessman, and Megan E. Bowers - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Raymond Miller, # 4 Certification of Shuzo Maruyama, # 5 Certification of Christian Chessman, # 6 Certification of Megan E. Bowers)(Biggs, Brian) (Entered: 04/27/2023) (Certification of Christian Chessman) (1) |
| Apr 27, 2023 | 127 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Raymond Miller, Shuzo Maruyama, Christian Chessman, and Megan E. Bowers - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Raymond Miller, # 4 Certification of Shuzo Maruyama, # 5 Certification of Christian Chessman, # 6 Certification of Megan E. Bowers)(Biggs, Brian) (Entered: 04/27/2023) (Certification of Megan E. Bowers) (1) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Main Document) (7) |
| Apr 24, 2023 | 125 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Main Document) (7) |
| Apr 24, 2023 | 125 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 18) (30) |
| Apr 24, 2023 | 125 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 19) (30) |
| Apr 24, 2023 | 125 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 20) (30) |
| Apr 24, 2023 | 125 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 21) (30) |
| Apr 24, 2023 | 125 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 22) (30) |
| Apr 24, 2023 | 125 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 23) (30) |
| Apr 24, 2023 | 125 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 24) (23) |
| Apr 24, 2023 | 125 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Exhibit PTX Exhibits-part 1) (30) |
| Apr 24, 2023 | 125 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Exhibit PTX Exhibits-part 2) (30) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit DTX Exhibits-part 1) (24) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit DTX Exhibits-part 2) (8) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit DTX Exhibits-part 3) (30) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit DTX Exhibits-part 4) (30) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 1) (11) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 2) (27) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 3) (18) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 4) (28) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 5) (26) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 6) (30) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 7) (30) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 8) (30) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 9) (30) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 10) (30) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 11) (30) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 12) (30) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 13) (30) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 14) (30) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 15) (3) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 16) (30) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 17) (30) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibits DTX 0004 - 0235) (30) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibits DTX 0004 - 0235) (30) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibits DTX 0004 - 0235) (30) |
| Apr 24, 2023 | 124 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 22 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibits DTX 0004 - 0235) (30) |
| Apr 21, 2023 | 123 | ORDER re (129 in 1:19-cv-02321-CFC, 158 in 1:19-cv-02368-CFC-JLH, 120 in 1:19-cv-02309-CFC, 153 in 1:19-cv-02342-CFC-JLH) STIPULATION and Order Regarding Post-Trial Briefing: Defendants' Opening Post-trial Brief: April 20, 2023; Defendants' Proposed Findings of Fact April 20, 2023; Plaintiffs' Answering Post-trial Brief May 4, 2023; Plaintiffs' Proposed Findings of Fact May 4, 2023; Defendants' Reply Post-trial Brief May 11, 2023; The parties will separately submit hyperlinked briefs May 12, 2023. Signed by Judge Colm F. Connolly on 4/21/2023. (nmf) (Entered: 04/21/2023) (7) |
| Apr 20, 2023 | 120 | STIPULATION and [Proposed] Order Regarding Post-Trial Briefing Schedule by Natco Pharma Ltd., Natco Pharma, Inc.. (Cragg, Tyler) (Entered: 04/20/2023) (7) |
| Apr 20, 2023 | 121 | Proposed Findings of Fact by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Certificate of Compliance)(Farnan, Kelly) (Main Document 121 replaced on 4/28/2023) (nmf, ). (Attachment 1 replaced on 4/28/2023) (nmf, ). (Entered: 04/20/2023) (Main Document) (30) |
| Apr 20, 2023 | 122 | POST TRIAL BRIEF (Defendants' Opening) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Certificate of Compliance)(Farnan, Kelly) (Entered: 04/20/2023) (Main Document) (30) |
| Apr 20, 2023 | 121 | Proposed Findings of Fact by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Certificate of Compliance)(Farnan, Kelly) (Main Document 121 replaced on 4/28/2023) (nmf, ). (Attachment 1 replaced on 4/28/2023) (nmf, ). (Entered: 04/20/2023) (Certificate of Compliance) (1) |
| Apr 20, 2023 | 122 | POST TRIAL BRIEF (Defendants' Opening) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Certificate of Compliance)(Farnan, Kelly) (Entered: 04/20/2023) (Certificate of Compliance) (1) |
| Apr 11, 2023 | 118 | Official Transcript of Bench Trial held on March 29, 2023 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: bonnie_archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 5/2/2023. Redacted Transcript Deadline set for 5/12/2023. Release of Transcript Restriction set for 7/10/2023. (nmf) (Entered: 04/11/2023) (0) |
| Apr 11, 2023 | 119 | Official Transcript of Bench Trial held on March 30, 2023 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: bonnie_archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 5/2/2023. Redacted Transcript Deadline set for 5/12/2023. Release of Transcript Restriction set for 7/10/2023. (nmf) (Entered: 04/11/2023) (0) |
| Mar 28, 2023 | 117 | STIPULATION Seeking to Update Both Sides' Trial Exhibit Lists, by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Amended PTO Ex. 7, # 2 Amended PTO Ex. 8)(Balick, Steven) (Entered: 03/28/2023) (Main Document) (6) |
| Mar 28, 2023 | 117 | STIPULATION Seeking to Update Both Sides' Trial Exhibit Lists, by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Amended PTO Ex. 7, # 2 Amended PTO Ex. 8)(Balick, Steven) (Entered: 03/28/2023) (Amended PTO Ex. 7) (23) |
| Mar 28, 2023 | 117 | STIPULATION Seeking to Update Both Sides' Trial Exhibit Lists, by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Amended PTO Ex. 7, # 2 Amended PTO Ex. 8)(Balick, Steven) (Entered: 03/28/2023) (Amended PTO Ex. 8) (10) |
| Mar 27, 2023 | 113 | REDACTED VERSION of (136 in 1:19-cv-02342-CFC-JLH, 104 in 1:19-cv-02309-CFC, 140 in 1:19-cv-02368-CFC-JLH, 113 in 1:19-cv-02321-CFC) Proposed Pretrial Order (Volume I of III) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 1-25)(Mayo, Andrew) (Entered: 03/27/2023) (Main Document) (30) |
| Mar 27, 2023 | 114 | REDACTED VERSION of (141 in 1:19-cv-02368-CFC-JLH, 137 in 1:19-cv-02342-CFC-JLH, 105 in 1:19-cv-02309-CFC, 114 in 1:19-cv-02321-CFC) Proposed Pretrial Order (Volume II of III) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 26, # 2 Exhibit 27)(Mayo, Andrew) (Entered: 03/27/2023) (Main Document) (2) |
| Mar 27, 2023 | 115 | REDACTED VERSION of (138 in 1:19-cv-02342-CFC-JLH, 142 in 1:19-cv-02368-CFC-JLH, 115 in 1:19-cv-02321-CFC, 106 in 1:19-cv-02309-CFC) Proposed Pretrial Order (Volume III of III) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 28-29)(Mayo, Andrew) (Entered: 03/27/2023) (Main Document) (2) |
| Mar 27, 2023 | 116 | REDACTED VERSION of (117 in 1:19-cv-02321-CFC, 109 in 1:19-cv-02309-CFC, 141 in 1:19-cv-02342-CFC-JLH, 146 in 1:19-cv-02368-CFC-JLH) Proposed Pretrial Order, by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 1-13)(Mayo, Andrew) (Entered: 03/27/2023) (Main Document) (30) |
| Mar 27, 2023 | 115 | REDACTED VERSION of (138 in 1:19-cv-02342-CFC-JLH, 142 in 1:19-cv-02368-CFC-JLH, 115 in 1:19-cv-02321-CFC, 106 in 1:19-cv-02309-CFC) Proposed Pretrial Order (Volume III of III) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 28-29)(Mayo, Andrew) (Entered: 03/27/2023) (Exhibit 28-29) (30) |
| Mar 27, 2023 | 116 | REDACTED VERSION of (117 in 1:19-cv-02321-CFC, 109 in 1:19-cv-02309-CFC, 141 in 1:19-cv-02342-CFC-JLH, 146 in 1:19-cv-02368-CFC-JLH) Proposed Pretrial Order, by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 1-13)(Mayo, Andrew) (Entered: 03/27/2023) (Exhibit 1-13) (30) |
| Mar 27, 2023 | 113 | REDACTED VERSION of (136 in 1:19-cv-02342-CFC-JLH, 104 in 1:19-cv-02309-CFC, 140 in 1:19-cv-02368-CFC-JLH, 113 in 1:19-cv-02321-CFC) Proposed Pretrial Order (Volume I of III) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 1-25)(Mayo, Andrew) (Entered: 03/27/2023) (Exhibit 1-25) (30) |
| Mar 27, 2023 | 114 | REDACTED VERSION of (141 in 1:19-cv-02368-CFC-JLH, 137 in 1:19-cv-02342-CFC-JLH, 105 in 1:19-cv-02309-CFC, 114 in 1:19-cv-02321-CFC) Proposed Pretrial Order (Volume II of III) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 26, # 2 Exhibit 27)(Mayo, Andrew) (Entered: 03/27/2023) (Exhibit 26) (30) |
| Mar 27, 2023 | 114 | REDACTED VERSION of (141 in 1:19-cv-02368-CFC-JLH, 137 in 1:19-cv-02342-CFC-JLH, 105 in 1:19-cv-02309-CFC, 114 in 1:19-cv-02321-CFC) Proposed Pretrial Order (Volume II of III) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 26, # 2 Exhibit 27)(Mayo, Andrew) (Entered: 03/27/2023) (Exhibit 27) (30) |
| Feb 21, 2023 | 112 | Letter to The Honorable Colm F. Connolly from Kelly E. Farnan regarding Trial Schedule. (Farnan, Kelly) (Entered: 02/21/2023) (2) |
| Feb 4, 2023 | 111 | Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding Plaintiffs' Request to Postpone the February 7 Trial. (Balick, Steven) (Entered: 02/04/2023) (2) |
| Feb 3, 2023 | 110 | Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding the February 7 Trial. (Balick, Steven) (Entered: 02/03/2023) (1) |
| Feb 2, 2023 | 109 | [SEALED] Proposed Pretrial Order by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Mayo, Andrew) (Entered: 02/02/2023) (0) |
| Jan 30, 2023 | 108 | Official Transcript of Pretrial Conference held on January 26, 2023 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: bonnie_archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 2/21/2023. Redacted Transcript Deadline set for 3/2/2023. Release of Transcript Restriction set for 5/1/2023. (nmf) (Entered: 01/30/2023) (44) |
| Jan 23, 2023 | 107 | SO ORDERED, re 103 STIPULATION of infringmement of claim 13 of the '284 patent by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. Signed by Judge Colm F. Connolly on 1/23/2023. (nmf) (Entered: 01/23/2023) (5) |
| Jan 19, 2023 | 103 | STIPULATION of infringmement of claim 13 of the '284 patent by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) (Entered: 01/19/2023) (5) |
| Jan 19, 2023 | 104 | [SEALED] Proposed Pretrial Order (Volume 1 of 3) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 1-25 (Volume 1 of 3))(Mayo, Andrew) (Entered: 01/19/2023) (0) |
| Jan 19, 2023 | 105 | [SEALED] Proposed Pretrial Order (Volume 2 of 3) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 26-27 (Volume 2 of 3))(Mayo, Andrew) (Entered: 01/19/2023) (0) |
| Jan 19, 2023 | 106 | [SEALED] Proposed Pretrial Order (Volume 3 of 3) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 28-29 (Volume 3 of 3))(Mayo, Andrew) (Entered: 01/19/2023) (0) |
| Dec 28, 2022 | 101 | Official Transcript of In-Person Status and Scheduling Conference held on December 21, 2022 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: bonnie_archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/18/2023. Redacted Transcript Deadline set for 1/30/2023. Release of Transcript Restriction set for 3/28/2023. (nmf) (Entered: 12/28/2022) (83) |
| Dec 28, 2022 | 102 | STANDING ORDER REGARDING BRIEFING IN ALL CASES. Associated Cases: 1:22-cv-01611-CFC et al.(kmd) (Entered: 12/28/2022) (2) |
| Dec 27, 2022 | 100 | REDACTED VERSION of (109 in 1:19-cv-02321-CFC, 99 in 1:19-cv-02309-CFC, 21 in 1:21-cv-00838-CFC, 8 in 1:22-cv-01480-CFC, 131 in 1:19-cv-02342-CFC-JLH, 134 in 1:19-cv-02368-CFC-JLH) Letter by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Balick, Steven) (Entered: 12/27/2022) (8) |
| Dec 20, 2022 | 99 | [SEALED] Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding the Parties' Joint Submission Concerning Issues Relevant to the December 21 Status and Scheduling Conference. (Balick, Steven) (Entered: 12/20/2022) (0) |
| Jun 30, 2022 | 95 | Redacted Document (30) Docket Text: REDACTED VERSION of (95 in 1:19-cv-02321-CFC, 118 in 1:19-cv-02342-CFC-JLH, 120 in 1:19-cv-02368-CFC-JLH, 89 in 1:19-cv-02309-CFC) Proposed Pretrial Order (Volume I of IV) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Jun 30, 2022 | 96 | Redacted Document (30) Docket Text: REDACTED VERSION of (121 in 1:19-cv-02368-CFC-JLH, 96 in 1:19-cv-02321-CFC, 119 in 1:19-cv-02342-CFC-JLH, 90 in 1:19-cv-02309-CFC) Proposed Pretrial Order (Volume II of IV) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Jun 30, 2022 | 97 | Redacted Document (30) Docket Text: REDACTED VERSION of (120 in 1:19-cv-02342-CFC-JLH, 97 in 1:19-cv-02321-CFC, 91 in 1:19-cv-02309-CFC, 122 in 1:19-cv-02368-CFC-JLH) Proposed Pretrial Order (Volume III of IV) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Jun 30, 2022 | 98 | Redacted Document (30) Docket Text: REDACTED VERSION of (98 in 1:19-cv-02321-CFC, 121 in 1:19-cv-02342-CFC-JLH, 92 in 1:19-cv-02309-CFC, 123 in 1:19-cv-02368-CFC-JLH) Proposed Pretrial Order (Volume IV of IV) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Jun 27, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: The 6/30/2022 Final Pretrial Conference and the 7/11/2022 Bench Trial are canceled. They will be rescheduled at a later date. Ordered by Judge Colm F. Connolly on 6/27/2022. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC-JLH, 1:19-cv-02368-CFC-JLH(nmf) |
| Jun 24, 2022 | 94 | Letter (1) Docket Text: Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding the Parties' Joint Response to the Court's Inquiry Concerning Possible Referral to Magistrate Judge Hall. (Balick, Steven) |
| Jun 22, 2022 | N/A | Telephone Conference (0) Docket Text: Minute Entry for proceedings held before Judge Colm F. Connolly - Telephone Conference held on 6/22/2022. (Court Reporter not present.) Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC-JLH, 1:19-cv-02368-CFC-JLH(nmf) |
| Jun 21, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER Setting Teleconference: Counsel for Plaintiffs shall coordinate the call and email the dial-in information to chambers. (A Telephone Conference is set for 6/22/2022 at 10:00 AM Telephonically before Judge Colm F. Connolly.) Ordered by Judge Colm F. Connolly on 6/21/2022. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC-JLH, 1:19-cv-02368-CFC-JLH(nmf) |
| Jun 10, 2022 | 93 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants' Joint 282 Notice filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Jun 9, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Tiffany K. Sung for Taiho Oncology, Inc. Taiho Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC-JLH, 1:19-cv-02368-CFC-JLH(twk) |
| Apr 4, 2022 | N/A | Case No Longer Referred to Mediation (0) Docket Text: CASE NO LONGER REFERRED to Chief Magistrate Judge Thynge for the purpose of exploring ADR. Pursuant to the Court's Standing Order No. 2022-2, dated March 14, 2022, "[u]nless otherwise directed by the Court, Magistrate Judges will no longer engage in alternative dispute resolution of patent and securities cases." See also 28 U.S.C. ยง 652(b). (Taylor, Daniel) |
| Feb 28, 2022 | 88 | SO ORDERED (3) Docket Text: SO ORDERED, re (112 in 1:19-cv-02368-CFC-JLH, 101 in 1:19-cv-02342-CFC-JLH, 87 in 1:19-cv-02309-CFC, 84 in 1:19-cv-02321-CFC) STIPULATION TO EXTEND TIME to File Daubert Motions to March 18, 2022, filed by Natco Pharma Ltd., Natco Pharma, Inc. Signed by Judge Colm F. Connolly on 2/28/2022. (kmd) |
| Feb 25, 2022 | 87 | Stipulation to EXTEND Time (3) Docket Text: STIPULATION TO EXTEND TIME to File Daubert Motions to March 18, 2022 - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Delcollo, Renee) |
| Feb 15, 2022 | 85 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Dr. Robert Wenslow on March 2, 2022 filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Balick, Steven) |
| Feb 15, 2022 | 86 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Allan S. Myerson on February 17, 2022 filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Feb 3, 2022 | 83 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Mohan Rao, Ph.D. on March 4, 2022, at 9:00 am filed by MSN Laboratories Private Ltd., MSN Pharmaceuticals Inc., Accord Healthcare Inc..(Ormerod, Eve) |
| Feb 3, 2022 | 84 | Notice to Take Deposition (3) Docket Text: NOTICE to Take Deposition of Richard M. Goldberg, M.D. on February 10, 2022 filed by Natco Pharma Ltd., Natco Pharma, Inc..(Delcollo, Renee) |
| Jan 24, 2022 | 80 | Notice to Take Deposition (3) Docket Text: NOTICE to Take Deposition of Ivan T. Hofmann on February 23, 2022 filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Jan 24, 2022 | 81 | Notice to Take Deposition (3) Docket Text: NOTICE to Take Deposition of Dr. Mark J. Ratain on March 2, 2022 filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Jan 24, 2022 | 82 | Notice to Take Deposition (3) Docket Text: NOTICE to Take Deposition of Dr. Mark J. Ratain on January 28, 2022 filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Jan 19, 2022 | 78 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME to complete expert discovery to March 4, 2022 - filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd.. (Dorsney, Kenneth) |
| Jan 19, 2022 | 79 | SO ORDERED (2) Docket Text: SO ORDERED, re [78] STIPULATION TO EXTEND TIME to complete expert discovery to March 4, 2022, filed by Eugia Pharma Specialities Ltd., Aurobindo Pharma U.S.A., Inc., Aurobindo Pharma Ltd. Re-Setting Scheduling Order Deadlines: Expert Discovery due by 3/4/2022. Signed by Judge Colm F. Connolly on 1/19/2022. (kmd) |
| Jan 18, 2022 | 77 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Dr. Howard S. Hochster on January 24, 2022 filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Nov 22, 2021 | 76 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Reply Expert Report of Howard S. Hochster, M.D. Regarding Infringement by the Eugia Defendants filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Nov 19, 2021 | 74 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Reply Expert Report of Robert Wenslow to the Responsive Expert Report of Dr. Allen Myerson regarding the validity of the '223 patent filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Nov 19, 2021 | 75 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants' (1) Reply Expert Report of Mark J. Ratain, M.D. to the Responsive Expert Report of Richard M. Goldberg, M.D. Regarding Validity Considerations of the '284 and '399 Patents and (2) Reply Expert Report of Ivan T. Hoffmann filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Sep 21, 2021 | 71 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Rebuttal Expert Report of Stephen G. Kunin filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Sep 21, 2021 | 72 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Responsive Expert Report of Allan S. Myerson, Ph.D Regarding Validity of the '233 Patent filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Sep 21, 2021 | 73 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of the Responsive Expert Report of Richard M. Goldberg, M.D. Regarding Validity Considerations of the '284 and '399 Patents and the Expert Report of Mohan Rao, Ph.D. filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Sep 20, 2021 | 69 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Eugia, Aurobindo and Natco's Responsive Expert Report of Mark Ratain, M.D. filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Sep 20, 2021 | 70 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Eugia and Aurobindo's Responsive Expert Report of Robert Wenslow filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Jul 23, 2021 | 68 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Opening Expert Report of Dr. Allan S. Myerson Regarding Infringement By Eugia Pharma Specialities Ltd., Aurobindo Pharma Ltd., and Aurobindo Pharma U.S.A., Inc., Opening Expert Report of Howard S. Hochster, M.D. Regarding Infringement by the Eugia Defendants, and Taiho's Disclosure of Second Supplemental Infringement Contentions Concerning Infringement of the Patents-In-Suit by the Eugia Defendants filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Balick, Steven) |
| Jul 22, 2021 | 66 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Opening expert report of Robert Wenslow, PH.D. filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Jul 22, 2021 | 67 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants' Expert Report of Mark J. Ratain, M.D. Concerning the Invalidity of U.S. Patent No. RE46,284 filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Jun 17, 2021 | 64 | Stipulation (4) Docket Text: STIPULATION and Proposed Order to Extend Time regarding Certain Scheduling Order Deadlines by Natco Pharma Ltd., Natco Pharma, Inc.. (Farnan, Kelly) |
| Jun 17, 2021 | 65 | SO ORDERED (4) Docket Text: SO ORDERED, re (64 in 1:19-cv-02309-CFC, 62 in 1:19-cv-02368-CFC, 61 in 1:19-cv-02321-CFC, 71 in 1:19-cv-02342-CFC) Stipulation filed by Natco Pharma Ltd., Natco Pharma, Inc. Signed by Judge Colm F. Connolly on 6/17/2021. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(fms) |
| Apr 16, 2021 | 63 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Aurobindo and Eugia's responses to Plaintiff's First Set of Requests for Admission (Nos. 1-171) filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Apr 14, 2021 | 62 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs' First Supplemental Objections and Responses to Defendants' First Set of Interrogatories (Nos. 1, 3) filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Apr 12, 2021 | 61 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants' First Set of Interrogatories (Nos. 1-6) filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Mar 18, 2021 | 58 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Hideki Kazuno on March 22, 2021 filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Mar 18, 2021 | 59 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Tomonobu Matsumi on March 23, 2021 filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Mar 18, 2021 | 60 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Akira Mita on March 26, 2021 filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Mar 17, 2021 | 57 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiffs' First Set of Requests for Admission to Defendants filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Mar 11, 2021 | 55 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs' Supplemental Initial Disclosures filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Mar 11, 2021 | 56 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of First Set of Interrogatories (Nos. 1-6) filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Mar 10, 2021 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: DI 54 and 55 Removed. Docket items filed in incorrect case. (apk) |
| Mar 10, 2021 | 54 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Dr. Rohit C. Ghan on March 16, 2021, filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Balick, Steven) |
| Feb 22, 2021 | 53 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Timothy Whitten on February 25, 2021 filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Feb 11, 2021 | 52 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Aurobindo's Objections to Taiho's 30(6)(6) Deposition Notice to Eugia filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Hitch, Cortlan) |
| Feb 8, 2021 | 51 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' response to Taiho's Second Set of Requests for Production (No. 47) filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Feb 4, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (50 in 1:19-cv-02309-CFC, 54 in 1:19-cv-02342-CFC, 49 in 1:19-cv-02368-CFC, 56 in 1:19-cv-02321-CFC) MOTION for Pro Hac Vice Appearance of Attorney Tiffany K. Sung filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc. Signed by Judge Colm F. Connolly on 2/4/2021. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(fms) |
| Feb 3, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [49] Stipulation filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc.. Ordered by Judge Colm F. Connolly on 2/3/2021. (fms) |
| Feb 3, 2021 | 50 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Tiffany K. Sung - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Feb 2, 2021 | 49 | Stipulation (2) Docket Text: STIPULATION to Amend Infringement Contentions by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Jan 7, 2021 | 48 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Taiho's Second Set of Requests for Production to the Eugia Defendants (No. 47) filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Dec 23, 2020 | 47 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of Taiho Pharmaceutical Co., Ltd.'s and Taiho Oncology, Inc.'s Objections and Responses to Defendants' Notice of Deposition under Fed. R. Civ. P. 30(b)(6) filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Dec 15, 2020 | 46 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants' Joint Notice of 30(b)(6) Deposition to Plaintiffs filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Dec 14, 2020 | 45 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of (1) Taiho's Notice of Rule 30(b)(6) Deposition to the Natco Defendants; (2) Taiho's Notice of Rule 30(b)(6) Deposition to the Eugia Defendants; and (3) Taiho's Notice of Rule 30(b)(6) Deposition to the MSN Defendants filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Balick, Steven) |
| Dec 10, 2020 | 44 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants' Joint Second Set of Requests for Production (Nos. 8-53) filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Balick, Steven) |
| Nov 10, 2020 | 43 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' Joint Second Set of Requests for Production to Plaintiffs (Nos. 8-53) filed by MSN Laboratories Private Ltd., MSN Pharmaceuticals Inc., Accord Healthcare Inc..(Ormerod, Eve) |
| Sep 25, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (48 in 1:19-cv-02342-CFC, 40 in 1:19-cv-02368-CFC, 42 in 1:19-cv-02309-CFC, 50 in 1:19-cv-02321-CFC) STIPULATION TO EXTEND TIME re: the deadline to substantially complete document production to December 4, 2020 filed by Natco Pharma Ltd., Natco Pharma, Inc.. Signed by Judge Colm F. Connolly on 9/25/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(fms) |
| Sep 24, 2020 | 42 | Stipulation to EXTEND Time (3) Docket Text: STIPULATION TO EXTEND TIME re: the deadline to substantially complete document production to December 4, 2020 - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Farnan, Kelly) |
| Sep 23, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (39 in 1:19-cv-02368-CFC, 41 in 1:19-cv-02309-CFC, 47 in 1:19-cv-02342-CFC, 49 in 1:19-cv-02321-CFC) Stipulation filed by Natco Pharma Ltd., Natco Pharma, Inc.. Signed by Judge Colm F. Connolly on 9/23/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(fms) |
| Sep 23, 2020 | 41 | Stipulation (3) Docket Text: STIPULATION and Proposed Order re Amended Invalidity Contentions by Natco Pharma Ltd., Natco Pharma, Inc.. (Farnan, Kelly) |
| Sep 16, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (48 in 1:19-cv-02321-CFC, 40 in 1:19-cv-02309-CFC, 46 in 1:19-cv-02342-CFC, 38 in 1:19-cv-02368-CFC) STIPULATION and Order Regarding Claim Construction filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., ORDER, terminating Deadlines and Hearings: The 2/18/2021 Markman Hearing is canceled and all other deadlines relating to claim construction are vacated. Signed by Judge Colm F. Connolly on 9/16/2020. (nmf) |
| Sep 14, 2020 | 40 | Stipulation (7) Docket Text: STIPULATION and Proposed Order Regarding Claim Construction, by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Balick, Steven) |
| Sep 1, 2020 | 39 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Taiho's Preliminary Identification of Claim Terms that Need Construction And Proposed Claim Constructions filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Aug 25, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (38 in 1:19-cv-02309-CFC, 44 in 1:19-cv-02342-CFC, 36 in 1:19-cv-02368-CFC, 43 in 1:19-cv-02321-CFC) STIPULATION TO EXTEND TIME to Exchange Identification of Claim Terms and Proposed Constructions to September 1, 2020 filed by Natco Pharma Ltd., Natco Pharma, Inc. Signed by Judge Colm F. Connolly on 8/25/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(nmf) |
| Aug 25, 2020 | 38 | Stipulation to EXTEND Time (4) Docket Text: STIPULATION TO EXTEND TIME to Exchange Identification of Claim Terms and Proposed Constructions to September 1, 2020 - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Farnan, Kelly) |
| Aug 11, 2020 | 37 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Joint Initial Invalidity Contentions filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Jul 15, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [36] STIPULATION TO EXTEND TIME to: 1) Submit Invalidity Contentions; 2) Exchange Indentification of Terms and Proposed Constructions; and 3) File Joint Claim Construction Chart to 1) August 11, 2020; 2) August 25, 2020; and 3) September 14, 2020, respecti filed by Natco Pharma Ltd., Natco Pharma, Inc. Ordered by Judge Colm F. Connolly on 7/15/2020. (fms) |
| Jul 9, 2020 | 36 | Stipulation to EXTEND Time (5) Docket Text: STIPULATION TO EXTEND TIME to: 1) Submit Invalidity Contentions; 2) Exchange Indentification of Terms and Proposed Constructions; and 3) File Joint Claim Construction Chart to 1) August 11, 2020; 2) August 25, 2020; and 3) September 14, 2020, respectively - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Farnan, Kelly) |
| Jun 29, 2020 | 35 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Eugia and Aurobindo's responses to Taiho's First Set of Joint Interrogatories (Nos. 1-4) filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Jun 5, 2020 | 34 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Taiho's First Set of Joint Interrogatories to Defendants filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| May 29, 2020 | 33 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Taiho's Disclosure of Infringement Contentions Concerning Infringement of the Patents-In-Suit by the Eugia Defendants filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| May 27, 2020 | 32 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Responses to First Set of Requests for Production (Nos. 1-46) filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| May 26, 2020 | 31 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants' First Set of Requests for Production (Nos. 1-7) filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| May 14, 2020 | 30 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs' Initial Disclosures related to Electronically Stored Information filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Apr 28, 2020 | 29 | Protective Order (26) Docket Text: PROTECTIVE ORDER. Signed by Judge Colm F. Connolly on 4/28/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(fms) |
| Apr 27, 2020 | 28 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Taiho's First Set of Requests for Production to The Eugia Defendants filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Apr 24, 2020 | 27 | Proposed Order (25) Docket Text: PROPOSED ORDER (Proposed Protective Order) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Apr 23, 2020 | 26 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Joint First Set of Requests for Production (Nos. 1-7) filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Apr 21, 2020 | 25 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' ANDA Product and related FDA Correspondence filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Apr 20, 2020 | 23 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Rule 26(a)(1) disclosures and (2) Paragraph 3 disclosures filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Apr 20, 2020 | 24 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs' Initial Disclosures filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Balick, Steven) |
| Apr 15, 2020 | N/A | Case Referred to Mediation (0) Docket Text: CASE REFERRED to Chief Magistrate Judge Mary Pat Thynge for Mediation. Please see Standing Order dated January 20, 2016, regarding disclosure of confidential ADR communications. A link to the standing order is provided here for your convenience at https://www.ded.uscourts.gov/sites/ded/files/forms/StandingOrderforADR-Mediation.pdf Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(cak) |
| Apr 14, 2020 | 22 | Scheduling Order (26) Docket Text: SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Joinder of Parties due by 10/23/2020. Amended Pleadings due by 10/23/2020. Fact Discovery completed by 4/6/2021. Expert Discovery due by 12/21/2021. Joint Claim Construction Brief due by 12/14/2020. A Markman Hearing is set for 2/18/2021 at 09:00 AM in Courtroom 4B before Judge Colm F. Connolly. Proposed Pretrial Order due by 6/9/2022. A Final Pretrial Conference is set for 6/30/2022 at 04:00 PM in Courtroom 4B before Judge Colm F. Connolly. A Bench Trial is set for 7/11/2022 at 08:30 AM in Courtroom 4B before Judge Colm F. Connolly. Signed by Judge Colm F. Connolly on 4/14/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(nmf) |
| Apr 13, 2020 | N/A | Remark (0) Docket Text: The April 15, 2020 Scheduling Conference is cancelled per the filing of the Letter and Unopposed Scheduling Order in accordance with the Court's Order of March 12, 2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(nmf) |
| Apr 13, 2020 | 19 | Letter (1) Docket Text: Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding the Parties' Jointly Proposed Scheduling Order. (Balick, Steven) |
| Apr 13, 2020 | 20 | Proposed Order (26) Docket Text: PROPOSED ORDER (Proposed Scheduling Order) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Balick, Steven) |
| Apr 13, 2020 | 21 | Answer to Counterclaim (12) Docket Text: ANSWER to [15] Answer to Complaint, Counterclaim by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Balick, Steven) |
| Apr 9, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Molly Hayssen for Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(kmd) |
| Apr 3, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (19 in 1:19-cv-02321-CFC, 18 in 1:19-cv-02309-CFC, 16 in 1:19-cv-02368-CFC, 21 in 1:19-cv-02342-CFC) MOTION for Pro Hac Vice Appearance of Attorney Molly Hayssen filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc.. Signed by Judge Colm F. Connolly on 4/3/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(fms) |
| Apr 3, 2020 | 18 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Molly Hayssen - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Mar 27, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [17] MOTION for Pro Hac Vice Appearance of Attorney William D. Hare and Attorney Christopher Casieri filed by Eugia Pharma Specialities Ltd., Aurobindo Pharma U.S.A., Inc., Aurobindo Pharma Ltd. Signed by Judge Colm F. Connolly on 3/27/2020. (nmf) |
| Mar 27, 2020 | 17 | Motion for Leave to Appear Pro Hac Vice (4) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney William D. Hare and Attorney Christopher Casieri - filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd.. (Dorsney, Kenneth) |
| Mar 23, 2020 | 15 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint, , COUNTERCLAIM against All Plaintiffs by Aurobindo Pharma Ltd., Eugia Pharma Specialities Ltd., Aurobindo Pharma U.S.A., Inc..(Dorsney, Kenneth) |
| Mar 23, 2020 | 16 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aurobindo Pharma Limited for Aurobindo Pharma U.S.A., Inc.; Corporate Parent Curepro Parenterals Limited, Corporate Parent Celon Laboratories Private Limited for Eugia Pharma Specialities Ltd. filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd.. (Dorsney, Kenneth) |
| Mar 12, 2020 | 14 | Order Setting Scheduling Conference (3) Docket Text: Order Setting Scheduling Conference: A Scheduling Conference is set for 4/15/2020 at 03:30 PM in Courtroom 4B before Judge Colm F. Connolly. If the parties have no disputes about scheduling, the Court will not require the parties to appear at a conference. Signed by Judge Colm F. Connolly on 3/12/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(nmf) |
| Feb 25, 2020 | 13 | Letter (2) Docket Text: Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding Plaintiffs' Response to the Court's January 27, 2020 Order Regarding Coordination of Proceedings. (Balick, Steven) |
| Jan 27, 2020 | 12 | Order (3) Docket Text: ORDER, on or before February 27, 2020, counsel for plaintiffs shall inform the court as to whether the need for coordinated discovery and/or Markman proceedings is anticipated and, if so, when a joint scheduling conference might most efficiently be conducted. ORDER, Setting Deadlines: Notice of Compliance deadline set for 2/27/2020. Signed by Judge Colm F. Connolly on 1/27/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(nmf) |
| Jan 23, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Michael Kaminski for Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(kmd) |
| Jan 23, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Liane M. Peterson for Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(kmd) |
| Jan 23, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Bradley Roush for Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-02368-CFC, 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC(mal) |
| Jan 22, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (10 in 1:19-cv-02342-CFC, 11 in 1:19-cv-02309-CFC, 11 in 1:19-cv-02321-CFC, 11 in 1:19-cv-02368-CFC) MOTION for Pro Hac Vice Appearance of Attorney Michael D. Kaminski, Liane M. Peterson, and Bradley Roush filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc. Signed by Judge Colm F. Connolly on 1/22/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(fms) |
| Jan 22, 2020 | 11 | Motion for Leave to Appear Pro Hac Vice (7) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Michael D. Kaminski, Liane M. Peterson, and Bradley Roush - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Dec 30, 2019 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [10] MOTION Seeking to Extend the Answer Deadlines of Defendants Eugia Pharma Specialities Ltd. and Aurobindo Pharma U.S.A., Inc. (UNOPPOSED) filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc. Set/Reset Answer Deadlines: Aurobindo Pharma U.S.A., Inc. answer due 3/23/2020; Eugia Pharma Specialities Ltd. answer due 3/23/2020.. Signed by Judge Colm F. Connolly on 12/30/2019. (fms) |
| Dec 27, 2019 | 10 | Motion for Miscellaneous Relief (2) Docket Text: MOTION Seeking to Extend the Answer Deadlines of Defendants Eugia Pharma Specialities Ltd. and Aurobindo Pharma U.S.A., Inc. (UNOPPOSED) - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Balick, Steven) |
| Dec 26, 2019 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC (rjb) |
| Dec 26, 2019 | 9 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc.: For Aurobindo Pharma Ltd. waiver sent on 12/23/2019, answer due 3/23/2020. (Balick, Steven) |
| Dec 20, 2019 | N/A | No Summons Issued (0) Docket Text: No Summons Issued. (amf) |
| Dec 20, 2019 | N/A | Summons Issued (0) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Aurobindo Pharma U.S.A., Inc. on 12/20/2019; Eugia Pharma Specialities Ltd. on 12/20/2019. (sam) |
| Dec 20, 2019 | 7 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc.. Aurobindo Pharma U.S.A., Inc. served on 12/20/2019, answer due 1/10/2020. (Balick, Steven) |
| Dec 20, 2019 | 8 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc.. Eugia Pharma Specialities Ltd. served on 12/20/2019, answer due 1/10/2020. (Balick, Steven) |
| Dec 19, 2019 | 1 | Main Document (27) Docket Text: COMPLAINT FOR PATENT INFRINGEMENT - filed against Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., and Eugia Pharma Specialities Ltd. - Magistrate Consent Notice to Pltf. (Filing fee $ 400, receipt number 0311-2806679) - filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc. (Attachments: # (1) Exhibits A-C, # (2) Civil Cover Sheet)(amf) |
| Dec 19, 2019 | 1 | Exhibits A-C (43) |
| Dec 19, 2019 | 1 | Civil Cover Sheet (1) |
| Dec 19, 2019 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (amf) |
| Dec 19, 2019 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 11/8/2019. Date of Expiration of Patent: SEE ATTACHED FORM.Thirty Month Stay Deadline: 3/23/2023. (amf) |
| Dec 19, 2019 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE46,284 E ;10,138,223 B2. (amf) |
| Dec 19, 2019 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka Holdings Co., Ltd. for Taiho Pharmaceutical Co., Ltd. - filed by Taiho Pharmaceutical Co., Ltd. (amf) |
| Dec 19, 2019 | 6 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka Holdings Co., Ltd. for Taiho Oncology, Inc. - filed by Taiho Oncology, Inc. (amf) |
| Dec 19, 2019 | 1 | Complaint* (1) |
